Fennec Pharmaceuticals Future Growth
Future criteria checks 5/6
Fennec Pharmaceuticals is forecast to grow earnings and revenue by 65.2% and 28.1% per annum respectively while EPS is expected to grow by 58.9% per annum.
Key information
65.2%
Earnings growth rate
58.9%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 28.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Nov 24Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 98 | 40 | 37 | 37 | 3 |
12/31/2025 | 60 | 1 | 15 | 15 | 5 |
12/31/2024 | 48 | -2 | 14 | 2 | 4 |
9/30/2024 | 49 | -1 | 24 | 24 | N/A |
6/30/2024 | 49 | 3 | 23 | 23 | N/A |
3/31/2024 | 45 | 3 | 27 | 27 | N/A |
12/31/2023 | 21 | -16 | -17 | -17 | N/A |
9/30/2023 | 13 | -20 | -19 | -19 | N/A |
6/30/2023 | 7 | -26 | -21 | -21 | N/A |
3/31/2023 | 3 | -26 | -21 | -21 | N/A |
12/31/2022 | 2 | -24 | -18 | -18 | N/A |
9/30/2022 | N/A | -21 | -15 | -15 | N/A |
6/30/2022 | N/A | -17 | -12 | -12 | N/A |
3/31/2022 | N/A | -16 | -13 | -13 | N/A |
12/31/2021 | N/A | -17 | -14 | -14 | N/A |
9/30/2021 | 0 | -16 | -14 | -14 | N/A |
6/30/2021 | 0 | -18 | -17 | -17 | N/A |
3/31/2021 | 0 | -19 | -15 | -15 | N/A |
12/31/2020 | 0 | -18 | -16 | -16 | N/A |
9/30/2020 | N/A | -18 | -14 | -14 | N/A |
6/30/2020 | N/A | -14 | -11 | -11 | N/A |
3/31/2020 | N/A | -14 | -10 | -10 | N/A |
12/31/2019 | N/A | -13 | -9 | -9 | N/A |
9/30/2019 | N/A | -12 | -10 | -10 | N/A |
6/30/2019 | N/A | -13 | -10 | -10 | N/A |
3/31/2019 | N/A | -11 | -9 | -9 | N/A |
12/31/2018 | N/A | -10 | -8 | -8 | N/A |
9/30/2018 | N/A | -9 | -6 | -6 | N/A |
6/30/2018 | N/A | -9 | N/A | -6 | N/A |
3/31/2018 | N/A | -8 | N/A | -5 | N/A |
12/31/2017 | N/A | -7 | N/A | -4 | N/A |
9/30/2017 | N/A | -6 | N/A | -3 | N/A |
6/30/2017 | N/A | -4 | N/A | -3 | N/A |
3/31/2017 | N/A | -3 | N/A | -2 | N/A |
12/31/2016 | N/A | -3 | N/A | -2 | N/A |
9/30/2016 | N/A | -2 | N/A | -2 | N/A |
6/30/2016 | N/A | -2 | N/A | -2 | N/A |
3/31/2016 | N/A | -1 | N/A | -2 | N/A |
12/31/2015 | N/A | -1 | N/A | -2 | N/A |
9/30/2015 | N/A | 1 | N/A | -2 | N/A |
6/30/2015 | N/A | 2 | N/A | -2 | N/A |
3/31/2015 | N/A | 1 | N/A | -2 | N/A |
12/31/2014 | N/A | -2 | N/A | -2 | N/A |
9/30/2014 | N/A | -2 | N/A | -2 | N/A |
6/30/2014 | N/A | -5 | N/A | -2 | N/A |
3/31/2014 | N/A | 3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FENC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: FENC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FENC is expected to become profitable in the next 3 years.
Revenue vs Market: FENC's revenue (28.1% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: FENC's revenue (28.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FENC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 08:38 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Difei Yang | Aegis Capital Corporation |
Naureen Quibria | Capital One Securities, Inc. |
Chase Knickerbocker | Craig-Hallum Capital Group LLC |